Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2016
ASCO 2016 – Lung Cancer
Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression
ASCO 2016 – Lung Cancer
,
ASCO
Conference Correspondent
Immune checkpoint inhibitors are active in the treatment of patients with non–small-cell lung cancer (NSCLC); since PD-L1 receptor expression is related to the mechanism of action of immune checkpoint inhibitors, expression of PD-L1 is being studied as a predictive biomarker for this therapy. Aguiar and colleagues evaluated the cost-effectiveness of nivolumab and pembrolizumab with and without the use of PD-L1 as a biomarker in patients with NSCLC.
1
A systematic literature review of online databases and oncology conference presentations was performed, and all studies that assessed PD-L1 expression as a biomarker were included regardless of the design of the trial, the agent used, tumor histology, or number of previous treatments. A decision-analytic model was developed to determine the cost-effectiveness of PD-L1 testing and second-line treatment with the 2 FDA-approved agents, nivolumab (nivo) and pembrolizumab (pembro), versus docetaxel (doce), in patients with advanced NSCLC. Health effects were expressed as quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated. A total of 13 studies (4 of which were randomized) with 2700 patients were retrieved and included in the model. PD-L1 expression was associated with a greater likelihood of response (relative risk [RR], 2.08; confidence interval [CI], 1.49-2.91), and this effect was more intense among nonsquamous (NSQ) tumors (RR, 3.13; CI, 2.15-4.54) than among those with squamous (SQ) histology (RR, 2.12; CI, 1.37-3.29). PD-L1 expression was also correlated with longer progression-free survival (hazard ratio [HR], 0.83; 95% CI, 0.74-0.93) and better overall survival (HR, 0.86; 95% CI, 0.76-0.97). Regarding cost-effectiveness, PD-L1 ≥1% improved incremental QALY of nivo
versus
doce for patients with NSQ tumors by 67%, (from 0.124 to 0.208) leading to a 40% reduction in the ICER (from US$ 176K to US$ 105K). Interestingly, this effect was not observed among patients with SQ tumors. For pembro, using a 50% cutoff instead of a 1% cutoff increased the incremental QALY by 18% (from 0.138 to 0.164), leading to a 15% reduction in ICER (from $163K to $138K). The authors concluded that use of PD-L1 expression as a biomarker was associated with higher activity with immune checkpoint inhibitors and may increase the cost-effectiveness of treatment with these agents, but this effect was less robust among patients with SQ NSCLC.
Aguiar PN, et al. ASCO 2016. Abstract 9033.
Related Articles
De-escalating Chemotherapy Possible in Low-Risk Patients with Advanced Testicular Cancer
By
Wayne Kuznar
ASCO
,
Genitourinary Cancers
April 2020, Vol 11, No 2
Read Article
A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies
By
Wayne Kuznar
ASCO
,
Genitourinary Cancers
April 2020, Vol 11, No 2
Read Article
MicroRNAs Have Promise as Biomarker in Testicular and Other Germ-Cell Tumors
By
Wayne Kuznar
ASCO
,
Genitourinary Cancers
April 2020, Vol 11, No 2
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma